Related Experiment Video
Updated: Jan 18, 2026
08:13
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
7.4K
Relationship between Dose, Factor IX Activity Levels and Bleeding Probability for rIX-FP Prophylaxis in Hemophilia B:
Sjoerd F Koopman1, Marjon H Cnossen2, Ron A A Mathot1
1Hospital Pharmacy-Clinical Pharmacology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Clinical Pharmacology and Therapeutics
|May 19, 2025
Summary
Pharmacokinetic-guided dosing of extended half-life factor IX (EHL-FIX) helps manage hemophilia B. Targeting 20 IU/dL trough FIX activity levels significantly reduces bleeding events, aiming for zero bleeds annually.
Area of Science:
- Hematology
- Pharmacokinetics and Pharmacodynamics
- Clinical Trials
Background:
- Hemophilia B treatment relies on factor IX (FIX) replacement therapy.
- Extended half-life factor IX (EHL-FIX) concentrates improve FIX exposure.
- Individualized dosing is crucial for effective hemophilia B management.
Purpose of the Study:
- To analyze the relationship between dose, FIX activity levels, and bleeding in hemophilia B patients.
- To evaluate the efficacy of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP).
- To establish optimal target FIX activity levels for reducing bleeding.
Main Methods:
- Combined data from five clinical trials involving hemophilia B patients.
- Utilized a parametric repeated time-to-event (RTTE) model to analyze bleeding probability.
- Included 2,493 FIX activity levels and 514 bleeds from 114 patients.
Main Results:
- A baseline bleeding rate of 7.3 bleeds/year was observed with zero FIX activity.
- A 50% reduction in bleeding probability occurred at 12 IU/dL FIX activity.
- Targeting 20 IU/dL trough FIX activity resulted in a median annual bleeding rate (ABR) of zero.
Conclusions:
- Individualized FIX activity targets, considering bleeding tendency and other factors, are essential.
- EHL-FIX concentrate rIX-FP demonstrates effectiveness in reducing bleeding events.
- Targeting trough FIX activity levels of 20 IU/dL is associated with zero median ABR in hemophilia B.
Related Concept Videos
01:21Drug Accumulation During Multiple Dosing: Repetitive IV Injections
256
Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
256
01:09One-Compartment Open Model for IV Bolus Administration: Estimation of Elimination Rate Constant, Half-Life and Volume of Distribution
857
The one-compartment open model is a simplified approach used in pharmacokinetics to understand the distribution and elimination of a drug administered through an intravenous bolus. This model assumes rapid drug dispersal throughout the body and elimination using a first-order process. Key pharmacokinetic parameters, such as the elimination rate constant (k), half-life (t1/2), and the apparent volume of distribution (Vd), can be estimated from this model. The elimination rate is calculated...
857
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
409
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
409
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.7K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.7K
01:29Venous Thrombosis III: Interprofessional Care
280
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
280
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.1K